Hexagon Nutrition Limited, a research-driven, pure-play nutrition platform founded in 1993 by the Kelkar family, is launching its Mainboard initial public offering (IPO). The subscription bidding window officially opens on Friday, June 5, 2026, and closes on Tuesday, June 9, 2026. Transitioning from its origins as a micro-formulations supplier, the company has transformed into an integrated player offering solutions across clinical nutrition, mass food fortification, and global humanitarian therapeutic feeding.
As the bidding cycle opens, the corporate issue is generating significant discussion among institutional desks. At the upper price band of ₹45, Hexagon Nutrition commands an aggregate issue size of ₹138.87 Crore, presenting a micro-cap entry opportunity into India’s growing preventive healthcare and clinical wellness economy.
1. Key IPO Offer Details & Timelines
The public issue is structured as a 100% Book Built Issue designed to establish a formal public listing float on both the BSE and NSE platforms.
| Parameter | Official IPO Specifications (June 2026) |
| Bidding Window | June 5, 2026 (Opens) – June 9, 2026 (Closes) |
| Price Band | ₹42 to ₹45 per equity share (Face Value: ₹1) |
| Lot Size (Minimum) | 333 Shares (Minimum retail investment: ₹14,985) |
| Total Issue Size | 3,08,59,704 Equity Shares (Aggregating to ₹138.87 Crore) |
| Issue Composition | 100% Offer for Sale (OFS) (No fresh issue component) |
| Lead Managers | Cumulative Capital Private Ltd. & Catalyst Capital Partners Ltd. |
| Registrar to the Issue | KFin Technologies Limited |
| Basis of Allotment Date | Wednesday, June 10, 2026 |
| Expected Listing Date | Friday, June 12, 2026 |
The Capital Allocation Structure: Because this offering is structured entirely as an Offer for Sale (OFS), existing legacy promoters and investors (including Arun Purushottam Kelkar, Subhash Purushottam Kelkar, Aditya Kelkar, and Nutan Subhash Kelkar) are paring their holdings. No fresh capital will flow back into the company’s operational bank accounts; the entire ₹138.87 crore will be distributed directly to the selling shareholders.
2. Core Business Architecture: A Three-Pronged Nutrition Model
Hexagon Nutrition has built a specialized product engine that insulates its revenue from dependency on a single distribution model. The company operates through three distinct business vectors:
A. B2C Branded Wellness & Clinical Care
The company develops, manufactures, and markets its own premium proprietary clinical nutrition and lifestyle supplement portfolios. These are distributed via a pan-India omnichannel network of 358+ distributors covering retail pharmacies, hospital networks, and e-commerce applications. Key product lines include:
- Pentasure: A flagship brand targeting adult clinical care, oncology metabolic support, and diabetic wellness.
- Obesigo: A clinically tested weight-management formulation.
- Pediagold: Specialized pediatric nutrition supplements.
- Nutrone: A recently introduced critical care and therapeutic portfolio.
B. B2B2C Customized Micronutrient Premixes
Hexagon acts as an essential business-to-business supply partner to major Indian and multinational fast-moving consumer goods (FMCG) corporations. It designs and blends customized vitamin and mineral premix formulations that industrial food companies use for mass food fortification (e.g., enriching milk, flour, and edible oils).
C. ESG & International Humanitarian Aid
The company manufactures Ready-to-Use Therapeutic Foods (RUTF) and specialized Micronutrient Powders (MNPs). These products are supplied directly to global non-governmental organizations, public health institutions, and United Nations-led health initiatives to combat severe acute malnutrition across emerging global sectors.
D. Manufacturing & Infrastructure Footprint
Hexagon operates four integrated production plants: three in India—located in Nasik (Maharashtra), Chennai SEZ, and Thoothukudi SEZ (Tamil Nadu)—and one international manufacturing facility in Tashkent, Uzbekistan. Its plants inside the Special Economic Zones (SEZs) provide strategic logistics, duty-free raw material procurement, and tax advantages for its expanding export channels, which ship products to more than 75 countries.
3. Deep-Dive Financial Scorecard: Accelerating Earnings Realizations
Hexagon’s financial filings in its Red Herring Prospectus (RHP) showcase a small-cap business experiencing sudden operational leverage, with bottom-line growth significantly outstripping its top-line revenue expansion.
Consolidated Income & Profit Trends
- FY23 Operational Revenue: ₹278.50 Crore | Net Profit (PAT): ₹5.82 Crore
- FY24 Operational Revenue: ₹297.73 Crore | Net Profit (PAT): ₹12.21 Crore
- FY25 Full-Year Revenue: ₹324.93 Crore (▲ 9.1% YoY growth)
- FY25 Full-Year Net Profit (PAT): ₹24.38 Crore (▲ 99.6% YoY growth)
- Nine Months Ended Dec 31, 2025 (9M FY26): ₹276.00 Crore Revenue with a net profit of ₹27.00 Crore.
Core Operational Efficiency and Return Ratios
- EBITDA Margin: Logged at 14.03% for the trailing nine-month tracking window, reflecting a steady rise from 10.31% in FY25 due to a richer mix of high-margin B2C branded products over bulk premixes.
- PAT Margin Progression: Advanced significantly from 2.07% in FY23 to 7.36% in FY25, hitting an elite 9.81% during 9M FY26.
- Return on Equity (ROE): Settled at a highly competitive 13.02% (with Return on Net Worth at 12.12%).
- Conservative Debt Profile: A key fundamental positive is Hexagon’s tight restriction on balance sheet leverage. The company reduced its aggregate borrowings to log an incredibly low Debt-to-Equity (D/E) ratio of just 0.18x, leaving the company protected from high interest rate environments.
4. Key Investment Risks: The Bear Case
- The 100% OFS Structure: Because this public issue contains zero fresh issue components, the company will not secure any growth capital to expand its in-house R&D facilities or immediately clear its remaining ₹26.6 crore debt.
- Raw Material Margin Sensitivity: Sourcing high-purity vitamins, mineral isolates, and milk proteins occurs without rigid, long-term contractual pricing agreements. Sudden supply chain disruptions or global commodity inflation loops could lead to compressed profit margins.
- Subsidiary Underperformance: As disclosed in its risk factors, certain international subsidiary units have experienced losses in recent cycles. If underperformance continues, it may require capital diversions from core domestic units to support these lines.
- New Product Adoption Risk: Brand extensions like the newly launched Nutrone line carry execution risk. If healthcare networks and retail consumers show slow adoption patterns, it could lead to inventory write-offs and marketing losses.
5. Grey Market Premium (GMP) and Market Valuation Analysis
In unlisted sessions, the Grey Market Premium (GMP) for Hexagon Nutrition is currently hovering at zero. This flat unlisted premium suggests that the broader market is anticipating a neutral or par listing around the upper price band of ₹45 per share, reflecting the quiet primary market conditions.
From a valuation standpoint, utilizing its post-IPO annualized EPS of ₹2.93 against the upper price band of ₹45, the stock is being offered at an attractive Price-to-Earnings (P/E) multiple of approximately 15.36x. For a company operating with a 14% EBITDA margin and nearly doubling its net profits over consecutive fiscal cycles, this multiple represents a significant discount compared to listed healthcare and FMCG-adjacent wellness peers, which frequently command trading multiples well north of 35x.
6. Final Strategic Verdict: Subscribe for Long-Term Value
Fundamentally, Hexagon Nutrition Limited presents a solid, low-debt “Value-Oriented Niche Play in India’s Nutritional Transformation.”
While short-term listing gain hunters are likely to stay on the sidelines due to a flat grey market premium and the lack of fresh capital expansion funds inside a 100% OFS design, patient investors should look directly at the underlying numbers. The dramatic acceleration in PAT margin to 9.81% and the low debt-to-equity ratio of 0.18x demonstrate excellent internal financial health.
Supported by its global export network spanning 75 countries, critical integration with United Nations health mandates, and an appealing entry valuation of 15.3x P/E, subscribing to this issue provides an attractive entry point to hold a high-potential micro-cap compounding asset for the long term.
FAQ Section
What are the open and close dates for the Hexagon Nutrition IPO?
The Mainboard public issue opens for subscription on Friday, June 5, 2026, and officially concludes on Tuesday, June 9, 2026. Eligible applications can be submitted through standard ASBA or UPI platforms during this window.
What is the lot size and minimum cost structure for retail applicants?
The retail lot size is fixed at 333 shares. At the peak price band of ₹45 per share, this translates to a minimum retail application investment of ₹14,985. Retail investors can bid for a maximum of 13 lots (4,329 shares) totaling ₹1,94,805.
What is the current Grey Market Premium (GMP) for Hexagon Nutrition?
The current Grey Market Premium (GMP) stands at ₹0, indicating that the unlisted market expects the stock to debut close to its official upper cutoff price of ₹45 when it lists on June 12, 2026.
Disclaimer: The views expressed are for informational purposes only and do not constitute financial advice. Investing in stocks and IPOs involves significant risk. forgeup.in is not liable for any financial losses. Always consult a certified investment advisor before making any decisions.